SCHEMBL30867869

SCHEMBL30867869

Cc1cnn(C2COC2)c1N1CCN(C(=O)OC(C)(C)C)C2CC21

nearest known ligand 0.34

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 4/20 0.34
▸ GPR119 Q8TDV5 2/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ THRB P10828 1/20 0.33
▸ LMNA P02545 1/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.32
▸ NR1H2 P55055 2/20 0.32
▸ NR1H3 Q13133 2/20 0.32
▸ SPR P35270 1/20 0.32
▸ TP53 P04637 2/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ HSD11B1 P28845 1/20 0.31
▸ MAPT P10636 1/20 0.31
▸ ACACB O00763 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30867870 0.90 NR1H2 (0.34) HDAC1GPR119NR1H2NR1H3HSD11B1
SCHEMBL30867873 0.89 HDAC1 (0.39) HDAC1NR1H2NR1H3
SCHEMBL30867686 0.85 HSD11B1 (0.35) HDAC1GPR119MEN1KMT2AHSD11B1
SCHEMBL38653820 0.83 ACACB (0.36) GPR119CYP1A2POLBCYP3A4CYP2C19
SCHEMBL30867805 0.81 NR1H2 (0.33) HDAC1GPR119NR1H2NR1H3HSD11B1
SCHEMBL30867765 0.81 GPR119 (0.51) GPR119THRBLMNASPRTP53
SCHEMBL30867690 0.76 GRM5 (0.35) GPR119LMNANPSR1SPRHSD11B1
SCHEMBL30867853 0.76 GRM5 (0.35) GPR119LMNANPSR1SPRHSD11B1
SCHEMBL30911162 0.73 GPR119 (0.40) GPR119POLBLMNANPSR1TP53
SCHEMBL30911221 0.73 GPR119 (0.40) GPR119POLBLMNANPSR1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260132143-A1 HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF AMGEN INC. (US) 2026-05-14 — — US disclosed
EP-4598917-A1 HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF Amgen Inc. (US) 2025-08-13 — — EP disclosed
WO-2024076674-A1 HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF AMGEN INC. (US) 2024-04-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260132143-A1 HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF KRAS, NRAS, HRAS HDAC1 3058/4885GPR119 2581/4885CYP1A2 3928/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback